Stock Analysis on Net
Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Paying user area

Try for free

Edwards Lifesciences Corp. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Edwards Lifesciences Corp., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Accounts payable
Employee compensation and withholdings
Accrued rebates
Property, payroll, and other taxes
Research and development accruals
Legal and insurance
Taxes payable
Fair value of derivatives
Accrued marketing expenses
Accrued professional services
Accrued realignment reserves
Accrued relocation costs
Other accrued liabilities
Accrued and other liabilities
Operating lease liabilities, current portion
Short-term debt
Contingent consideration liabilities
Current liabilities
Long-term debt
Contingent consideration liabilities
Taxes payable
Operating lease liabilities, long-term portion
Uncertain tax positions
Litigation settlement accrual
Other liabilities
Long-term liabilities
Total liabilities
Preferred stock, $.01 par value, no shares outstanding
Common stock, $1.00 par value
Additional paid-in capital
Retained earnings
Accumulated other comprehensive loss
Treasury stock, at cost
Stockholders’ equity
Total liabilities and stockholders’ equity

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Edwards Lifesciences Corp. current liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2019 to 2020 and from 2020 to 2021.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Edwards Lifesciences Corp. long-term liabilities as a percentage of total liabilities and stockholders’ equity increased from 2019 to 2020 but then decreased significantly from 2020 to 2021.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Edwards Lifesciences Corp. total liabilities as a percentage of total liabilities and stockholders’ equity increased from 2019 to 2020 but then decreased significantly from 2020 to 2021.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Edwards Lifesciences Corp. stockholders’ equity as a percentage of total liabilities and stockholders’ equity decreased from 2019 to 2020 but then increased from 2020 to 2021 exceeding 2019 level.